Stern Adam K's Form 4 filing
Matinas BioPharma Holdings, Inc. (MTNB) · filed Aug 13, 2026
- Accession no.
- 0000921895-26-002109
- Filed
- Aug 13, 2026, 4:04 PM ET
- Trade date
- Oct 16, 2025-Jul 10, 2026
- Filing delay
- 301 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 8 derivative transactions. It was filed 301 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stern Adam KCIK 0001403497 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 31, 2025 | Common Stock, par value $0.0001 per share | XIn-the-money exerciseAcquired | +92,100 | $0.6446 | +$59,367.66 | 113,450 | Indirect | |
| Jul 10, 2026 | Common Stock, par value $0.0001 per share | XIn-the-money exerciseAcquired | +344,710 | $0.35 | +$120,648.5 | 416,900 | Indirect | |
| Jul 10, 2026 | Common Stock, par value $0.0001 per share | XIn-the-money exerciseAcquired | +630,335 | $0.35 | +$220,617.25 | 743,785 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2025 | Common Stock, par value $0.0001 per share | JOtherAcquired | +800,000 | $0.6446 | +$515,680 | 800,000 | Indirect | |
| Oct 16, 2025 | Common Stock, par value $0.0001 per share | JOtherAcquired | +452,218 | $0.586 | +$155.29 | 265 | Indirect | |
| Oct 31, 2025 | Common Stock, par value $0.0001 per share | XIn-the-money exerciseDisposed | −92,100 | $0.6446 | −$59,367.66 | 630,335 | Indirect | |
| Jul 10, 2026 | Common Stock, par value $0.0001 per share | XIn-the-money exerciseDisposed | −630,335 | $0.35 | −$220,617.25 | 0 | Indirect | |
| Jul 10, 2026 | Common Stock, par value $0.0001 per share | AGrant or awardAcquired | +630,335 | $0.35 | +$220,617.25 | 630,335 | Indirect | |
| Jul 10, 2026 | Common Stock, par value $0.0001 per share | XIn-the-money exerciseDisposed | −344,710 | $0.35 | −$120,648.5 | 0 | Indirect | |
| Jul 10, 2026 | Common Stock, par value $0.0001 per share | AGrant or awardAcquired | +344,710 | $0.35 | +$120,648.5 | 344,710 | Indirect | |
| Jul 10, 2026 | Common Stock, par value $0.0001 per share | JOtherAcquired | +141,462 | $0.35 | +$49,511.7 | 141,462 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.